Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ishares Msci Spain ETF (EWP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ishares Msci Spain ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.91 (market cap $29.60B), while Ishares Msci Spain ETF trades at $62.76. The key difference: Ishares Msci Spain ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWP | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $62.66 |
52-Week Low | $205.48 | $47.02 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
EWP trades at $62.76, up 0.56% with strong technical momentum as moving averages signal bullish alignment. The stock shows mixed oscillators with RSI indicating potential overbought conditions. Recent corporate actions include a $0.92 dividend scheduled for June 2026, providing income appeal to investors.
The bullish technical setup suggests near-term upside potential, though overbought RSI levels warrant caution. European market strength and ECB policy stability create favorable conditions, but reliance on macroeconomic factors rather than company-specific fundamentals presents concentration risk for US investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →
